<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536272</url>
  </required_header>
  <id_info>
    <org_study_id>201900659</org_study_id>
    <secondary_id>848018014</secondary_id>
    <secondary_id>7969</secondary_id>
    <secondary_id>2019-004125-24</secondary_id>
    <nct_id>NCT04536272</nct_id>
  </id_info>
  <brief_title>Reduced Anticoagulation Targets in ECLS (RATE)</brief_title>
  <acronym>RATE</acronym>
  <official_title>Reduced Anticoagulation Targets in ECLS (RATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OLVG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS&#xD;
      diminish bleeding complications without an increase in thromboembolic complications or a&#xD;
      negative impact on outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: ECMO treatment has a mortality of 38%, for a large part treatment related due to&#xD;
      complications. The most feared complication is ischemic stroke for which heparin is&#xD;
      administered with an aPTT target 2.0-2.5 times baseline (approximately 60-75 sec).&#xD;
&#xD;
      However, there is no relation between aPTT and the occurrence of stroke (1.2%), but there is&#xD;
      a relation with the much more frequent occurrence of bleeding complications (55%) and blood&#xD;
      transfusion. Both are strongly related to outcome.&#xD;
&#xD;
      Objective: Our objective is to study if reduced anticoagulation targets diminish bleeding&#xD;
      complications without an increase in thromboembolic complications or a negative impact on&#xD;
      outcome.&#xD;
&#xD;
      Study design: Three-arm non-inferiority RCT.&#xD;
&#xD;
      Study population: All adult Dutch patients treated with ECMO during the 30 months of the&#xD;
      study.&#xD;
&#xD;
      Intervention: Randomization between heparin administration with a target of 2-2.5 times&#xD;
      baseline aPTT (usual care, about 60-75 sec.), 1.5-2.0 times baseline aPTT (45-60 sec.) or low&#xD;
      molecular weight heparin (LMWH) guided by weight and renal function.&#xD;
&#xD;
      Main study parameters/endpoints: The primary outcome parameter is a combined endpoint&#xD;
      consisting of: 1) major bleeding including hemorrhagic stroke according to the ELSO&#xD;
      definitions; 2) severe thromboembolic complication defined as ischemic stroke, limb ischemia&#xD;
      (not related with distal perfusion catheter), or acute pump failure with emergency exchange;&#xD;
      3) mortality at 6 months.&#xD;
&#xD;
      Secondary outcome parameters are: 1) blood transfusions; 2) health related quality of life&#xD;
      (HR-QoL) at 6 months; 3) exchange of the membrane oxygenator; 4) vessel thrombosis after ECMO&#xD;
      removal detected by echography; 5) pulmonary embolism; 6) costs; 7) the individual components&#xD;
      of the composite outcome; and 8) all thromboembolic complications combined.&#xD;
&#xD;
      Expected outcomes: We expect that with a target of 1.5-2.0x baseline aPTT or with LMWH the&#xD;
      primary composite endpoint will be reached in 60% of patients compared to 70% in usual care.&#xD;
      To show non-inferiority with a significance level (alpha) of 5%, power of 80% and a&#xD;
      non-inferiority limit (delta) of 7.5% the corresponding sample size is 91 patients per group.&#xD;
      In other words, if there is a true difference in favor of the experimental treatment of 10%,&#xD;
      then 91 patients per group are required to be 80% sure that the upper limit of a one-sided&#xD;
      95% confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a&#xD;
      difference in favor of the standard group of more than 7.5%. To compensate for a lower effect&#xD;
      and drop-outs 330 patients will be enrolled. Apart from anticoagulation targets, treatment&#xD;
      will be as usual so study participation will not lead to a burden for the patient, e.g. no&#xD;
      extra blood sampling, tests or visits. After 6 months the patients will be contacted for a&#xD;
      short questionnaire to measure health-related quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization between anticoagulation targets during ECLS of: 1). 2-2.5 times baseline aPTT (usual care, about 60-75 sec.), 2). 1.5-2.0 times baseline aPTT (45-60 sec.) or 3). LMWH guided by weight and renal function.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemorrhagic complications</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>Severe hemorrhagic complications will be registered according to the Extracorporeal Life Support Organization (ELSO) definitions for major bleeding and is defined as clinically overt bleeding with a decrease in hemoglobin of at least 1,24 mmol/L (2 g/dl)/24 hours, or a transfusion requirement of â‰¥ 3 EH RBC over that same time period. Bleeding that is retroperitoneal, pulmonary or involves the central nervous system, or bleeding that requires surgical intervention is also considered major bleeding.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe thromboembolic complications</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>Severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months after ECLS</time_frame>
    <description>Mortality at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>Number of blood transfusions during ECLS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at 6 months</measure>
    <time_frame>6 months after ECLS</time_frame>
    <description>Quality of life (HR-QoL) measured 6 months after decannulation from ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exchange of the membrane oxygenator</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>Number of echanges of the membrane oxygenator during ECLS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel thrombosis after ECLS removal</measure>
    <time_frame>After ECLS completion, an average of 14 days</time_frame>
    <description>Vessel thrombosis after ECLS removal detected by echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost- effectiveness</measure>
    <time_frame>6 months after ECLS</time_frame>
    <description>Cost- effectiveness will be based on reduced costs of blood transfusions and interventions for bleeding (e.g. surgery, interventional radiology) as well as improved outcome. All medical cost items expected to be affected by the ECMO therapy will be measured and valued according to the Dutch standard guidelines for economic evaluations, e.g. blood transfusion, number of ECMO replacements, surgery, and hospital length of stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolism</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>The occurrence of Pulmonary embolism during ECLS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All thromboembolic complications combined</measure>
    <time_frame>Through ECLS completion, an average of 14 days</time_frame>
    <description>The occurrence of all thromboembolic complications combined during ECLS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Heart Failure</condition>
  <condition>Respiratory Failure</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>Bleeding</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Target of 2-2.5 times baseline aPTT (usual care, about 60-75)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Target of 1.5-2.0 times baseline aPTT (45-60 sec.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMWH guided by weight and renal function.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of LMWH guided by weight and renal function during ECLS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.</description>
    <arm_group_label>Target of 1.5-2.0 times baseline aPTT (45-60 sec.)</arm_group_label>
    <arm_group_label>Target of 2-2.5 times baseline aPTT (usual care, about 60-75)</arm_group_label>
    <other_name>Unfractionated heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMWH</intervention_name>
    <description>Administration of LMWH guided by weight and renal function during ECLS.</description>
    <arm_group_label>LMWH guided by weight and renal function.</arm_group_label>
    <other_name>Dalteparine</other_name>
    <other_name>Enoxaparine</other_name>
    <other_name>Nadroparine</other_name>
    <other_name>Tinzaparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECMO treatment during the study period in one of the participating centers&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in whom the ECMO is only used to bridge a procedure&#xD;
&#xD;
          -  Vital indication for robust anticoagulation (e.g. mechanic valve, pulmonary embolism)&#xD;
&#xD;
          -  History of heparin induced thrombocytopenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W.M. van den Bergh, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>O. van Minnen</last_name>
    <phone>+31503616161</phone>
    <email>o.van.minnen@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>W.M. van den Bergh, PhD, MD</last_name>
    <phone>+31503616161</phone>
    <email>w.m.van.den.bergh@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. van den Brule, PhD, MD</last_name>
      <email>Judith.vandenBrule@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.S.R. Delnoij, PhD, MD</last_name>
      <email>thijs.delnoij@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG, location East</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1091AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Balzereit, PhD, MD</last_name>
      <email>a.balzereit@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1100DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.P.J. Vlaar, PhD, MD</last_name>
      <email>a.p.vlaar@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Kuijpers, MD</last_name>
      <email>m.kuijpers@isala.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Scholten, PhD, MD</last_name>
      <email>e.scholten@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.J. Maas, PhD, MD</last_name>
      <email>j.j.maas@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. dos Reis Miranda, PhD, MD</last_name>
      <email>d.dosreismiranda@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.M. van den Bergh, PhD, MD</last_name>
      <phone>+31503616161</phone>
      <email>w.m.van.den.bergh@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>O. van Minnen</last_name>
      <phone>+31503616161</phone>
      <email>o.van.minnen@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Walter M. van den Bergh</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal membrane oxygenation</keyword>
  <keyword>Extracorporeal life support</keyword>
  <keyword>ECMO</keyword>
  <keyword>ECLS</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal which is approved by an independent review panel.&#xD;
To achieve aims in the approved proposal.&#xD;
Proposals should be directed to w.m.van.den.bergh@umcg.nl, requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

